• ქართული
  • English
  • Sanofi eyes more growth this year as it narrows focus

    Sanofi on Thursday said it was expecting earnings per share to grow around 5 percent at constant exchange rates in 2020, weeks after pledging to focus on vaccines and key treatments like its eczema medicine Dupixent until 2022.

    Market Quotes by TradingView